Mary Szela was appointed chief executive officer of Aegerion Pharmaceuticals in January 2016. Previously, Ms. Szela was chief executive officer of Melinta Therapeutics until August 2015, where she led the company’s revitalization effort, accelerated the lead asset into three phase programs and oversaw key business development transactions to monetize non-core assets. Before joining Melinta, she held various management positions at Abbott Laboratories, most recently as senior vice president for global strategic marketing and services. From 2008 to 2010, Ms. Szela served as president of the $8 billion U.S. pharmaceuticals division, during which time she directed the development and launch of more than eight new pharmaceutical products and multi-billion dollar sales growth for Abbott’s flagship product, Humira®. Between 2002 and 2008, Ms. Szela managed several of Abbott’s billion-dollar U.S. pharmaceutical businesses, and was VP of U.S. commercial operations. Prior to 2001, Ms. Szela held a series of leadership positions in the Abbott Hospital Products Division. She currently serves as a member of the boards of Novo Nordisk, Coherus Biosciences, and Suneva Medical. Ms. Szela earned an M.B.A. and a B.S. in nursing from the University of Illinois.
Gregory Perry was appointed Chief Financial Officer of Aegerion Pharmaceuticals in July of 2015. Prior to that, Mr. Perry served as Chief Financial Officer of Eleven Biotherapeutics. Before joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics. Prior to joining InVivo, he served as the Executive Vice president and Chief Financial Officer of ImmunoGen. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer, Honeywell and General Electric. Mr. Perry serves on the board of directors of Ocata Therapeutics.
Ben Harshbarger previously served as General Counsel for Aegerion Pharmaceuticals since September 2016. Prior to that, he served as Aegerion’s Acting General Counsel, VP, EMEA Legal Counsel and as our VP, Deputy General Counsel of Aegerion. Before joining Aegerion, Mr. Harshbarger served as Senior Director, Corporate Counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012, and Senior Director, Deputy General Counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger holds a J.D. from Boston College Law School and a B.A. from the University of Richmond.
Dr. Orloff brings nearly 20 years of global experience in drug discovery and development. Prior to joining Aegerion, Dr. Orloff served as executive Vice President, Global Head of Research and Development, and Chief Scientific Officer of Baxalta, Inc., where he was responsible for advancing the company's pipeline across hematology, immunology and oncology. Prior to Baxter International's spinoff of its BioScience business to create Baxalta, Dr. Orloff held a similar role at Baxter. Prior to Baxter, he was Senior Vice President, Global Head of Clinical Development at Merck Serono Pharmaceuticals. Between 2003 and 2013, Dr. Orloff held a series of scientific leadership roles at Novartis Pharma AG, including senior vice president and Chief Medical Officer. Previously, he was a senior director at Merck Research Laboratories, where he began as an Associate Director in 1997. Dr. Orloff completed his internal medicine residency at University of Pittsburgh Medical Center and his endocrinology and metabolism fellowship at Yale University School of Medicine, where he also spent seven years on the faculty. He holds an M.D. from University of Vermont College of Medicine and a B.A. from Dartmouth College.
Roger Louis served as Aegerion Pharmceuticals' Senior Vice President, Global Chief Compliance Officer since November 2015. Mr. Louis has extensive experience in compliance and risk management, having served most recently as Senior Vice President, Compliance & Risk Management, Chief Compliance Officer at Cubist Pharmaceuticals prior to its acquisition by Merck. Mr. Louis joined Cubist from Biogen Idec where he was Senior Vice President, Chief Compliance Officer. From 1997 to 2012, he held positions of increasing responsibility at Genzyme Corporation, including Senior Vice President, Chief Compliance Officer. Mr. Louis began his legal career as an Associate at Hale & Dorr in Boston where he practiced corporate and securities law. Mr. Louis received his J.D. from University of Chicago School of Law and his B.A. from Tufts University.
Prior to Novelion, Linda Buono joined Aegerion in July 2016 as Senior Vice President of Human Resources. Prior to Aegerion, Linda spent more than 25 years at Immunogen where she held a variety of leadership positions in Human Resources. Linda is effective in managing all the critical tasks and responsibilities of the company’s HR function and has facilitated recruitment of top talent across the organization. Importantly, she possesses the critical soft skills needed to significantly improve the success of the company. Her core attributes include courage, judgment, influence, political agility and effective communication, all of which are having an impact on the improved culture of the organization.